(Mercaptoethyl)ammonium hydrogen tartrate
CAS: 27761-19-9
Rif. 3D-FM171255
1g | Fuori produzione | ||
2g | Fuori produzione | ||
5g | Fuori produzione | ||
250mg | Fuori produzione | ||
500mg | Fuori produzione |
Informazioni sul prodotto
- 2,3-Dihydroxybutanedioate
- 2-Aminoethanethiol
- Cystagon
- Cysteamine Bitartrate
- Ethanethiol, 2-amino-, (2R,3R)-2,3-dihydroxybutanedioate (1:1)
- Ethanethiol, 2-amino-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt)
- Ethanethiol, 2-amino-, [R-(R*,R*)]-2,3-dihydroxybutanedioate (1:1) (salt)
- Ethanethiol, 2-amino-, hydrogen tartrate
- Ethanethiol, 2-amino-, tartrate (1:1) (salt)
- Mercamine bitartrate
- Vedi altri sinonimi
- Mercaptoethylamine bitartrate
- Procysbi
- Rp 103
- Rp 104
- β-Mercaptoethylamine bitartrate
- β-Mercaptoethylamine hydrogen tartrate
- β-Mercaptoethylamine hydrotartrate
The experimental model of the controlled-release preparation of (mercaptoethyl)ammonium hydrogen tartrate is based on the hypothesis that a high resistance to hepatic steatosis can be achieved by a prolonged release of cysteamine. The drug was administered enterically, and it was found that the concentration in the portal vein is higher than in the portal vein. Cysteamine enters into liver cells and inhibits protein synthesis. Cysteamine has been shown to have an effect on infectious diseases such as cystinosis, and sodium citrate reduces the toxicity of cysteamine.